Canon Medical Systems unveils new top-level CT model and clinical progress of PCCT at RSNA 2023
By Oin Gyu, Medical News Reporter
Canon Medical Systems, with CEO Toshio Tagiguchi in attendance, made a significant impact at the Radiological Society of North America (RSNA 2023) event in Chicago, USA. At the event, the company revealed a new top-level CT model, advancements in photon counting computed tomography (PCCT), and next-generation advanced technology.
During RSNA 2023, Canon Medical Systems hosted an Innovation Theater session, a Lunch and Learn Symposium, and set up an exhibition booth to showcase their unique CT-focused technology.
Firstly, the company unveiled the new top CT model, ‘Aquillion One Insight Edition.’ This model supports more accurate and safer inspection by incorporating Peek’s upgraded deep learning technology and Instings workflow platform.
The Aquillion One Insight Edition was highlighted for its upgraded peak, a proprietary technology that increases the spatial resolution of deep CT images. This unique technology is only achievable with Canon Medical Systems’ Aquillion Precision CT image, offering a detector array of 0.25mm in size. Notably, the peak in the Aquillion Insight can now be applied to areas beyond the heart, including the lungs and abdomen, providing enhanced resolution.
In addition, Canon Medical Systems applied the Instings workflow platform to the Aquillion One Insight Edition for the first time, supporting various functions for fast, secure, and easy exploration. Among the supported functions include auto positioning, automatic scan planning, and a reduction in tube voltage for low-dose high-definition image examination.
Furthermore, Canon Medical Systems announced significant progress and future plans for PCCT, a next-generation cutting-edge technology that is expected to revolutionize imaging diagnostic technology.
PCCT utilizes CZT (cadmium-zinc-telluride) sensor-based imaging diagnostic systems to achieve better contrast and higher resolution images with a lower radiation dose than conventional CT. Clinical evaluation of PCCT is expected to begin in early 2024 with the goal of rapid commercialization, with Canon Medical Systems actively involved in advancing the development and clinical application of this innovative technology.
CEO of Canon Medical Systems Korea, Kim Young-jun, expressed the company’s commitment to introducing innovative technologies that prioritize the safety of patients and medical staff. He also emphasized their efforts to ensure the introduction of these technologies in Korea in the near future.
Overall, Canon Medical Systems’ participation at RSNA 2023 showcased their dedication to advancing imaging diagnostic technology, with the unveiling of new CT products and the promising future of next-generation PCCT technology.
(Source: Medical News, December 2023)
[의학신문·일간보사=오인규 기자] Canon Medical Systems (CEO Toshio Tagiguchi) participated in the Radiological Society of North America (RSNA 2023) held in Chicago, USA, and unveiled a new top-level CT model and clinical progress of photon counting computed tomography (PCCT), and next-generation advanced technology.
In this RSNA 2023, we implemented an Innovation Theater session, a Lunch and Learn Symposium, and an exhibition booth, and in particular showcased our unique CT-focused technology.
First up, the new top CT model ‘Aquillion One Insight Edition’<사진>‘ revealed. Aquillion One Insight Edition supports more accurate and safer inspection by applying Peek’s upgraded deep learning technology and Instings workflow platform.
The biggest feature of the Aquillian One Insight Edition is that it has an upgraded peak. PEAK is a proprietary technology that increases the spatial resolution of deep CT images based on learning, developed for the first time in the world by Canon Medical Systems.
Because PEAK uses the Aquillian Precision CT image, which contains a detector array of 0.25 mm in size, as a high-resolution training CT image, it is a unique technology that cannot be implemented with CT with a regular detector array of 0.6 mm or 0.625 mm in size.
The peak applied in Edition One of the Aquillian Insight presented at this RSNA has expanded its scope of application not only to the previously supported area of the heart but also the lungs and abdomen. In addition, by using a 1024 matrix, images can be practically enlarged up to 4 times compared to existing 512 matrix images, and even smaller areas can be seen clearly with higher resolution.
In addition, the Canon Medical Systems Instings workflow platform was applied for the first time to the Aquillian One Insight Edition in the top CT model. Instings supports a variety of functions for fast, secure and easy exploration.
Auto positioning is a function that automatically adjusts the position of the two cameras installed on the equipment to identify the patient’s entire body and photograph the exact area, making it more useful when photographing infected patients.
Automatic scan planning, which automatically plans the scan range, dose and exposure settings is also supported. In particular, Canon’s proprietary technology, 3D Landmark Scan, is a technology that supports scout shooting in 3D to establish the exact location inside the body before shooting images. Unlike 2D shooting, it captures not only the front and sides of the body but also the inside of the body in 3D, showing a shooting range setting accuracy of 97%.
In addition, the minimum tube voltage was reduced to 70kV and the current was increased to 1,400mA, making low-dose high-definition image examination possible even for trauma and obese patients. The time for one tube rotation was shortened from 0.275 seconds to 0.24 seconds, greatly expanding the range of cardiac CT imaging for patients with rapid heart rates.
Meanwhile, Canon Medical Systems received a lot of attention by announcing clinical research progress and future plans for PCCT, the next-generation cutting-edge technology.
PCCT is a cutting edge next generation technology that will lead the imaging diagnostic technology market in the future. It uses CZT (cadmium-zinc-telluride), Telluride, which is a single count It is an imaging diagnostic system that has a sensor in based on cadmium cadmium or silicon.
It is expected that better contrast and higher resolution images can be obtained with a much lower radiation dose than conventional CT, enabling accurate and precise lesion classification.
Canon Medical Systems acquired Redlen Technologies, a leading manufacturer of detection modules made of CZT, in 2021, and installed a PCCT prototype at the National Cancer Center in Japan to conduct preclinical testing. In addition, since April this year, we have been conducting joint research to collect and verify various clinical evidences with the Oncology Research and Clinical Trials Center of the National Cancer Center of Japan and the National Cancer Center of Eastern Japan.
In November, we are accelerating global clinical research for the commercialization of PCCT by signing a joint clinical research agreement with the Netherlands’ Radboud University Medical Center and Hiroshima University for the commercialization of PCCT.
Clinical evaluation of PCCT is expected to begin in early 2024 with the goal of rapid commercialization. Canon Medical Systems intends to continue to be actively involved in joint research with medical institutions around the world to advance the development and clinical application of innovative next-generation PCCT technology.
“Based on ‘innovation that starts with people,’ we introduce innovative technologies that support accurate examinations with the safety of patients and medical staff as the top priority,” said Kim Young-jun, CEO of Canon Medical Systems Korea . “Currently at RSNA, we are also introducing new CT products with the latest innovative technologies.” and the technologies of the future were revealed, achieving another innovation. “We will do our best to ensure that it is introduced in Korea in the near future,” he said.
#Canon #Medical #unveils #innovative #technology #RSNA
